Neurocrine Biosciences (STU:NB3) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NB3 Neurocrine Biosciences Inc STU:NB3
93 GF Score
Price €153.15
GF Value €166.59
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Neurocrine Biosciences's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

STU:NB3 vs VTRS, ELAN, UTHR: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurocrine Biosciences Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Margin of Safety % (DCF FCF Based) falls into.


STU:NB3
93GF Score
Neurocrine Biosciences Inc STU:NB3
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neurocrine Biosciences (STU:NB3) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €153.15 is trading 8.1% below its estimated GF Value™ of €166.59. GuruFocus considers Neurocrine Biosciences to be Fairly Valued.

Key valuation signals for STU:NB3:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €166.59 vs. price of €153.15 (8.1% below fair value)
  • GF Score™: 93/100 with 6 warning signs

No single metric tells the full story. See the STU:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
93GF Score

Get the complete analysis for STU:NB3

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€153.15
Price
€166.59
GF Value